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Abstract 
 Despite decades of intensive scientific and medical efforts to develop efficient and 
effective treatments for cancer, it remains one of the prime causes of death today. For example, 
in 2016, there will be an estimated 1,685,210 new cases of cancer and 595,690 deaths due to 
cancer in the United States alone (National Cancer Institute).  Worldwide in 2012, there were an 
estimated 14 million new cases of cancer and 8.2 million deaths due to cancer.  In order to come 
up with better methods of detection and more successful modes of treatment, it is crucial that 
scientists understand the depth of not only what causes cancer but also what sustains it. This 
literature review examines cancer as a metabolic disease. More specifically, it summarizes 
carbohydrate metabolism and compares and contrasts the roles of the glucose transporter, the 
metabolic enzymes hexokinase, pyruvate kinase, citrate synthase, succinate dehydrogenase, 
cytochrome c oxidase, ATP synthase, and the tumor suppressor protein p53 in normal versus 
cancer cells. The review focuses on the altered cellular function of these molecules and the 
significance of their dysfunctionality in the transformation of normal to cancer cells.
Introduction  
Research has established that cancer 
is not a single disease but multiple diseases 
and epigenetic change contributes to its 
formation (Hirschey et.al, 2015). Cancer is 
characterized by unrestrained cellular 
proliferation, which may arise from nuclear 
genetic mutations or from mitochondrial 
DNA damage which alters the metabolic 
pathways – a network of chemical reactions 
either building (anabolism) or breaking 
(catabolism) molecules in an organism – of 
a cell.  
The hallmarks of cancer comprise 
six biological functions acquired during the 
development of human tumors, which 
include: 1) cell proliferative signals; 2) 
evading growth suppressors (also known as 
tumor suppressors); 3) inhibition of 
apoptosis (cell death); 4) enabling 
replicative immortality; 5) inducing 
angiogenesis and 6) activating invasion and 
metastasis. Conceptual progress in the last 
decade has added two emerging hallmarks to 
this list: evading immune destruction and 
reprogramming of energy metabolism 
(Weinberg & Hanahan, 2011) 
This review focuses on several 
differences in carbohydrate energy 
metabolism between normal and cancer cells 
and their significance in the cause and/or 
maintenance of the malignant phenotype. 
Carbohydrate metabolism comprises the 
different biochemical processes responsible 
for anabolism and catabolism of 
carbohydrates in an organism. Glycolysis 
and the citric acid cycle are two of the many 
biochemical processes used by cells for the 
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catabolism of glucose molecules, which are 
ultimately converted into useable energy in 
the form of ATP. Normal cells produce up 
to 32 ATP molecules per glucose molecule 
oxidized through glycolysis, citric acid 
cycle, and oxidative phosphorylation. 2 ATP 
molecules are produced from glycolysis in 
the cytosol and the other 30 in the oxidative 
phosphorylation using NADH and FADH2 
generated from glycolysis and the citric acid 
cycle. 
In the 1920s, Dr. Otto Warburg first 
observed the glucose metabolism in normal 
vs. cancer cells. He observed that the 
amount of glucose uptake in cancer cells 
was significantly greater than that in normal 
cells. He also observed that while normal 
mammalian cells usually convert all of their 
glucose into pyruvate via glycolysis, cancer 
cells converted more than half of their 
glucose into lactate (M.D. Hirschey et.al, 
2015)  in the presence or absence of oxygen 
(Bensinger & Christofk, 2012). This effect is 
known as the Warburg effect (Bensinger & 
Christofk, 2012). However, the mechanism 
of how cancers do this is yet to be 
determined.  
One metabolic aberration in cancer 
cells includes a broken link between 
glycolysis and the oxidative phosphorylation 
(OP). OP is oxygen dependent whereas 
glycolysis is oxygen independent. Cancer 
cells take advantage of glycolysis being 
independent of oxygen and thus excel it, 
breaking the homeostatic link between 
glycolysis and OP. The rate of ATP 
production in cancer cells is 100 times faster 
than that of normal cells. Thus, even by 
taking an insufficient pathway for ATP 
production, cancer cells are able to 
proliferate at high rates. Where normal cells 
are strategically programmed to work 
together to build various types of tissues 
needed for organismic survival, cancer cells 
have a different agenda. All they want to do 
is make more copies of themselves and the 
Warburg effect helps them with that 
(Weinberg, 2014).  
1. Glucose transport 
Normal and cancer cells alike need 
glucose for survival. Our cells acquire 
glucose from the blood stream via 
transporters located on the cell’s membrane. 
The glucose transporters (GLUT) are a 
group of 14 different uniporter membrane 
proteins that transport glucose through the 
plasma membrane into the cell. GLUT-1, 
which is encoded by the SLC2A1 gene in 
humans, is of primary importance to this 
review (Serra et.al, 2014). In normal cells, 
the level of GLUT-1 on the membrane 
fluctuates depending on how much glucose 
is available in the blood stream, such that 
the GLUT-1 level is inversely proportional 
to glucose level. However, it has been 
observed that GLUT-1 is expressed in high 
levels in many tumors, regardless of the 
level of glucose present in the blood stream 
(Serra et.al, 2014). This allows for an 
increase in glucose uptake to serve the high 
energy demands of cancer cells (i.e, rapid, 
uncontrolled cell division). High levels of 
GLUT-1 are also found in fetal tissues, adult 
erythrocytes, and endothelial cells. 
Interestingly, cancer cells are known to 
mimic fetal and undifferentiated cells in 
many ways.  
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Fig. 1: Difference in Metabolism between Normal 
vs. Cancer cells. The figure shows the glucose 
metabolic pathway in a) a normal cell and b) in 
cancer cell. In a) a normal cell, glucose is transported 
into the cell via GLUT-1 where catabolism takes 
place through glycolysis, where glucose is committed 
to catabolism by HK (not shown) and broken down in 
to pyruvate by PKM-1. 2 ATP molecules are 
generated in this process. Pyruvate is then transported 
in to the mitochondria where it is converted to acetyl-
coA which goes through the citric acid cycle. The 
NADH and FADH2 generated from glycolysis and 
citric acid cycle goes through oxidative 
phosphorylation (OP) through which the proton 
gradient (not shown) is established, O2 is reduced to 
form water, and 32 ATP molecules are synthesized. 
Increase levels of P53 (refer to 5. P53) inhibits 
glycolysis when necessary blocking glucose 
metabolism with no net ATP production. In b) cancer 
cell, glucose is transported in the cell via GLUT-1 
where catabolism takes place through glycolysis, 
where glucose is committed to catabolism by HK2 
(not shown) and broken down in to pyruvate by 
PKM-2. Pyruvate is then converted to lactate by LDH 
and leaves the cell creating an acidic environment 
(not shown). The chain between glycolysis and OP is 
broken (marked as red) and P53 is either silenced or 
completely lost from the cell.  
 
2. Glycolysis 
Once glucose enters the cytosol, it can 
undergo oxidation by glycolysis, a series of 
10 enzyme catalyzed chemical reactions in 
which glucose is broken down to two 
pyruvate molecules (as shown in Fig.2). 
Energy is required in the first half of the 
process and then generated in the second 
half. For each glucose molecule, 2 
molecules of pyruvate, 2 NADH, and 2 ATP 
molecules are generated (Pratt & Cornely, 
2014). 
 
Fig.2: Glycolysis. A series of 10 enzyme catalyzed 
chemical reactions in which glucose is broken down 
to two pyruvate molecules. There is a preparatory 
phase where two ATP molecules are consumed and a 
payoff phase where 4 ATP and 2 NADH molecules 
are generated, producing a total of 2 ATP, 2 NADH, 
and 2 Pyruvate molecules in the end (Giri, 2016). 
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Hexokinase   
Hexokinase (HK) catalyzes the first 
step of glycolysis in the cytosol (in most 
glycolytic pathways) converting glucose to 
glucose-6-phosphate (G6P). This is a rate- 
limiting step for glycolytic pathway, which 
commits glucose molecules to undergo 
complete oxidation (Bioinformatics, 2016). 
The role of HK in committing glucose 
molecules to energy metabolism may play a 
crucial role in supporting cancer, since these 
cells require an abundance of glucose energy 
for survival. HK is an enzyme located on the 
outer membrane of mitochondria, which is 
expressed in four isoforms, HK1, HK2, 
HK3, and HK4 all of which are found in 
humans (Patra, et.al 2013). HK1 is common 
in various types of cells in adults, HK4 is 
common in liver and pancreatic cells, little is 
known about HK3, and high levels of HK2 
have been observed in many types of cancer 
including epithelial ovarian, breast, and 
colon cancer. 
 HK2 has two catalytic domains, the 
N- and C-terminals (Ahn et.al, 2009). Both 
domains have enzyme activity with N-
terminal having a higher activity than the C-
terminal. Even though there are two binding 
sites for glucose on HK2, only one molecule 
binds at a time. Studies suggest that when 
one glucose molecule binds on one of the 
two sites, it causes the enzyme to go through 
a conformational change, which then 
prevents another glucose molecule from 
binding to the enzyme during catalysis 
(Cardenas et.al, 1998). It is not completely 
known why HK2 has two glucose binding 
sites when it only catalyzes one molecule at 
a time.  
High levels of HK2 are of great 
significance to cancer cells as observed in 
many different studies. In one of the studies, 
tissues of 48 colorectal cancer patients were 
studied for mRNA expression of proteins 
including but not limited to HK2, GLUT-1, 
PKM2, and VDAC-1 (Graziano et.al, 2016). 
Significantly high levels of these proteins 
were observed in primary tumor and liver 
metastasis with respect to the levels in 
normal mucosa. Other experiments have 
shown enhanced glycolytic rate when 
solubilized HK2 was added in a liver tumor 
cytosol (Hirschey et.al, 2015). In mouse 
models of kRas-driven lung cancer and Erb-
driven breast cancer, HK2 was shown to be 
necessary to initiate and maintain tumor 
cells (Patra et.al, 2013).  
Studies have shown a correlation 
between low levels of HK2 and down-
regulation of the Warburg effect (a decrease 
in the rate of glycolysis). In one study of 
epithelial ovarian cancer (EOC), low levels 
of Glucose transporter 1 (GLUT1), HK2, 
and down-regulation of the Warburg effect 
and cell proliferation were observed when a 
transcription factor known as FOXM1 gene 
expression was suppressed (Wang et.al, 
2016). FOXM1 bind directly to the promoter 
region of GLUT1 and HK2 gene and 
promotes synthesis at the transcriptional 
level, so when FOXM1 was knocked down, 
the levels of GLUT1 and HK2 were 
observed to decrease (Wang et.al, 2016). In 
another study, the inhibition of HK2 was 
shown to improve the effects of anticancer 
drugs (Peng, et.al, 2009). Thus high levels 
of HK2 may very well be involved in the 
alteration of cancer cell’s metabolism and 
the transformation of normal cells into 
cancer cells. The mechanism of how HK2 
may be involved in tumorigenesis, however, 
is still unknown.  
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Pyruvate Kinase  
Pyruvate Kinase catalyzes the last 
step in glycolysis where it converts 
phospenolpyruvate (PEP) and ADP to 
pyruvate and ATP. This is another rate 
limiting step in the glycolytic path after 
HK2 (Bensinger & Christofk, 2012). The 
PKM gene encodes for isoenzymes PKM1 
and PKM2. They are located in the cytosol 
within the glycolytic enzyme “complex”. 
The two isoforms only differ in 23 amino 
acids within a 56 amino acid band on the C-
terminus. PKM1 is commonly found in 
normal cells and assures the import of 
pyruvate in to the mitochondria, whereas 
PKM2 is active in embryos and more 
common in tumor cells where it diverts 
pyruvate to lactate dehydrogenase-A (LDH-
A), which reduces pyruvate to lactate. Our 
focus is on PKM2 which is expressed in 
organs with high energy demands such as 
muscle, brain, and all cells that have high 
rate of nucleic acid synthesis, such as 
normal proliferating cells, embryonic cells, 
and tumor cells (Gupta & Bamezai, 2010).  
PKM2 is present in two forms, 
tetrameric and dimeric. The tetrameric form 
has high affinity to PEP and is highly active 
at physiological PEP concentration, whereas 
the dimeric form has low affinity to PEP and 
is almost inactive at physiological PEP 
concentration. The dimeric form of PKM2, 
termed as Tumor M2-PK, is observed in 
many tumor cells (Mazurek, et.al, 2005). An 
increase in glycolysis helps to meet energy 
demands of high synthesis in cancer cells 
and PKM-2 plays an important role in 
generating synthetic intermediates. The low 
tetramer to high dimer ratio of PKM2 effects 
the conversion of glucose. High levels of 
dimeric form of PKM2 favors the 
conversion of glucose to lactate, whereas the 
tetrameric form favors the conversion of 
glucose to pyruvate.  
The alteration of normal enzymes 
within the glycolytic complex hinders how 
the intermediates are processed. The shift 
from oxidative phosphorylation to glycolysis 
for ATP production with feedback inhibition 
accelerates glycolysis, which leads to 
enhanced lactate production. Glycolysis 
becomes the fastest way for energy 
production as well as the best pathway to 
synthesize nutrients (that are the 
intermediates) to help with cell proliferation.  
(Icard, 2011).  
In one study that investigated the 
effects of PKM2 expression in osteosarcoma 
(Liu, et.al, 2016); PKM2 expression was 
observed to be elevated in cancerous tissues 
with respect to the adjacent normal tissues. 
The same study also showed an overall 
decrease in patient survival rate in the 
presence of high PKM2 levels than low 
PKM2 levels. In another study, silencing of 
PKM2 was shown to increase docetaxel (a 
chemotherapy drug) sensitivity in cells 
leading to strong suppression of cell 
viability (Yuan, et.al, 2016). High levels of 
PKM2 can be detrimental for patients and 
inhibition may increase the survival rate. 
This suggests the great importance of PKM2 
levels present in cancer cells. 
Other experiments have also shown that 
the growth of tumors depend on PKM2 
expression, high levels of GLUT-1, and 
LDH-A. Inhibition of either of these 
proteins have been observed to noticeably 
slow down tumor growth. These 
observations show that the altered glucose 
metabolism of cancer cells creates a 
physiological system favorable for cancer 
growth and proliferation (Weinberg, 2014).  
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3. Citric Acid Cycle 
Citric acid cycle, also known as the 
Tricarboxcylic acid (TCA) or krebs cycle, is 
a pathway located in the inner matrix of 
mitochondria. When pyruvate enters the 
mitochondria it is converted into acetyl-co-
A, which then proceeds in the TCA cycle, 
producing 2 CO2, 3 NADH, 2 FADH2, and 1 
ATP molecule. Note that amino acids, fatty 
acids, and carbohydrates can enter the cycle 
and go through the same process as well. 
The cycle is a series of enzyme catalyzed 
chemical reactions (as shown in Fig. 3), 
where the intermediates can serve as 
precursors of many reactions and products 
of different biological molecules (Pratt and 
Cornely, 2014). 
 
Fig.3: Citric Acid Cycle. The cycle is a series of 
enzyme catalyzed chemical reactions that take place 
in the mitochondria to catabolize pyruvate. The 
intermediates can serve as precursors of many 
reactions and products of different biological 
molecules (not shown). 2 CO2, 1 ATP, 3 NADH, and 
2 FADH2 molecules are generated 
(http://www.chemistrylearning.com/krebs-cycle/). 
 
Citrate Synthase  
Citrate synthase (CS) is an enzyme 
in the first step in the citric acid cycle 
(commonly assumed to be the rate limiting 
step) in which it catalyzes the condensation 
reaction of acetyl-coA and oxaloacetate to 
citrate. It is located in the mitochondrial 
matrix, transcribed by the nuclear DNA, and 
serves as a central enzyme in the process of 
glucose oxidation. It is comprised of 437 
amino acids, which are organized into two 
subunits with 20 alpha helices each. Three 
quarters of the helices have tertiary structure 
while the remaining have irregular structure 
and a beta sheet composed of 13 amino acid 
residues. The active site is roughly located 
between the two subunits where each 
subunit has a binding site, one for acetyl-
coA and the other for oxaloacetate 
(http://pdb101.rcsb.org/motm/93). High 
levels of ATP:ADP, acetyl-coA:CoA, and 
NADH:NAD  ratio inhibit CS; these signal 
that the cell has enough energy and  does not 
need to generate more energy until the ATP, 
acetyl-coA, and NADH levels decline.  
The catalysis of the condensation 
reaction of acetyl-coA and oxaloacetate to 
citrate by CS means that CS activity is 
proportional to citrate concentration. 
Increase in CS activity will yield high levels 
of citrate, which has shown anti-cancer 
properties that sensitize cancer cells to 
chemotherapy (Icard, et.al, 2012). In normal 
cells, the Pasteur Effect – the process of 
fermentation inhibited in the presence of 
oxygen (opposite of the Warburg effect) – is 
regulated by ATP and citrate. Under 
hypoxic conditions, the cell undergoes 
oxidative stress that results in low level of 
ATP and citrate in the mitochondria. This in 
turn increases the activity of 
phosphofructokinase-1 (PFK1) – the enzyme 
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catalyst in the third step of glycolysis – 
which in turn increases the rate of glycolysis 
to generate sufficient energy to keep the cell 
alive (Icard, et.al, 2012).  
Alterations in CS activity have been 
observed in many types of cancers (Chen 
et.al, 2014). In a study of ovarian carcinoma, 
the cell line of benign tumor was compared 
with normal human ovarian surface 
epithelium, and ovarian tumor cell line was 
compared with ovarian cancer cell line 
(Chen et.al, 2014). High levels of CS were 
observed in benign versus normal and 
tumors versus cancer cell line. These 
observations show the proportionality 
between cell transformation and CS levels 
and suggest that CS expression is correlated 
with tumor progression. It has also been 
observed that the knock down of CS in 
ovarian cancer cell lines slowed down the 
process of cell proliferation and inhibited 
invasion and migration of cancer cells in 
vitro. The knock down also helped sensitize 
cancer cells to chemotherapeutic drugs like 
cisplatin, which subsequently showed 
enhanced apoptotic results (Chen et.al, 
2014). In another study, however, the effects 
of knocked down CS were analyzed in 
human cervical cancer cell lines in which 
the silencing of CS showed an increase in 
cell proliferation, invasion, and migration in 
vitro (Lin, et.al, 2012). The metabolic shift 
of normal cells to cervical tumor cells was 
observed and results showed that low levels 
of CS corresponded to the switch from 
normal aerobic respiration to glycolysis 
(Lin, et.al, 2012). The contradiction 
regarding the effects of CS activity in 
different types of cancer is one of the many 
examples demonstrating that cancer is not a 
single disease but multiple diseases with 
distinct alteration in metabolism that thus 
require different treatments. 
It is interesting to note how CS activity 
regulated in normal cells under hypoxic 
conditions resembles the activity in cancer 
cells. The majority of tumor cells are found 
to be hypoxic and exhibit the same kind of 
behavior, which is catabolizing glucose in to 
higher yields of lactate than pyruvate.  
Succinate Dehydrogenase  
Succinate Dehydrogenase (SD) is 
one of the many tumor suppressor protein 
(encoded by a tumor suppressor gene, which 
regulates cell cycle by slowing down cell 
division, repairing DNA, and inducing 
apoptosis when necessary) located on the 
inner membrane of the mitochondria (King 
et al, 2006). It is involved in both, the citric 
acid cycle and the oxidative phosphorylation 
(OP) also known as the electron transport 
chain (ETC), which will be discussed later 
in this review. SD catalyzes step 7 of the 
citric acid cycle and is also known as 
complex II in OP where it couples the 
oxidation of succinate to fumarate in the 
citric acid cycle with the reduction of 
ubiquinone to ubiquinol in OP. Mutations in 
SD are found to promote cancer 
transformation through the production of 
carcinogens (Ciriolo & Cardaci, 2012). The 
mechanism and detailed effects of SD in 
cancer metabolism is still under 
investigation.  
4. Oxidative Phosphorylation  
Oxidative Phosphorylation is the main 
source of ATP production in normal cells. It 
is the final stage of catabolism of metabolic 
fuels, a process whereby free energy from 
the transfer of electrons is conserved in a 
transmembrane gradient of protons that is 
then used to power ATP synthesis (Pratt & 
Cornely, 2014). The OP pathway is 
comprised of 5 complexes as shown in 
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Fig.4, two of which are of particular 
significance in cancer cell metabolism. 
 
Fig.4: Oxidative Phosphorylation. There are five 
complexes involved in oxidative phosphorylation 
located in the inner mitochondrial membrane space. 
Complexes I-IV are in sequence on the right and 
complex V is shown on the left. Complexes I and II 
take the electrons from NADH and FADH2 generated 
from the citric acid cycle and pass it on to complex 
III and IV through ubiquinone and cytochrome c. 
During this process, protons are pumped from the 
matrix into the intermembrane space creating a 
proton gradient. Complex V then utilizes the proton 
gradient to synthesize ATP from ADP and Pi 
(https://www.khanacademy.org/science/biology/cellu
lar-respiration-and-fermentation/oxidative-
phosphorylation/a/oxidative-phosphorylation-etc).  
Cytochrome c oxidase (Complex IV) 
Cytochrome c oxidase (COX), also 
known as complex IV, is a large 
transmembrane protein located on the inner 
membrane of mitochondria. It is the central 
part of the oxidative phosphorylation 
metabolic pathway where oxygen is 
reduced. In mammals, it is composed of 13 
subunits, 10 of which have a nuclear origin 
and the other three have a mitochondrion 
origin (Krieg, et.al, 2004). Each complex 
has multiple metal prosthetic groups that are 
integral to the electron transfer process. 
There are two hemes present on the 
complex, one of which forms a binuclear 
center (a3-CuB) that carries out oxygen 
reduction. Four cytochrome c molecules 
transfer 4 electrons, one at a time, to CuA, 
which passes the electrons to cytochrome, 
and then on to the binuclear center where 
oxygen is reduced and 2 water molecules are 
formed. During this process, COX attracts 8 
protons, 4 of which are used in the 
formation of water molecules and the other 
4 are pumped out in the intermembrane 
space enhancing the protein gradient (Pratt 
& Cornely, 2014). 
COX is present in three 
configurations: fully oxidized (also known 
as pulsed), partially reduced, and fully 
reduced. Different types of inhibitors have 
affinity towards different conformational 
states. Cyanide, for example, is a 
competitive inhibitor and has a high affinity 
to the partially reduced state of COX. It 
binds slowly but efficiently to binuclear site 
when the complex is in that state. On the 
other hand, high levels of ATP can 
allosterically inhibit cytochrome c oxidase 
(Arnold & Kadenbach, 1997). 
Since COX is a central part of the 
oxidative metabolism, an alteration in this 
enzyme may have proportional effects on 
alterations in metabolism seen in cancer 
cells (Krieg et.al, 2004). In cancer cells, the 
homeostasis between the glycolytic pathway 
and oxidative phosphorylation is disrupted. 
The high level of glycolysis is used to 
acquire immense level of ATP production 
and the cell is not dependent on oxidative 
phosphorylation (OP) to fulfill its energy 
needs, unlike normal cells. Studies have 
shown an increase in the level of nuclear 
encoded versus mitochondrial encoded COX 
subunits in tumor derived cell lines of 
prostate and urothelial epithelium (Krieg 
et.al, 2004). High activity of COX was also 
observed in these cell lines and was 
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correlated with an increase in glycolysis. 
High activity of COX is thought to assist 
tumor by depleting the citric acid cycle 
intermediates, which will lower the citrate 
concentration so it cannot inhibit PFK, 
therefore creating an environment that 
favors high rate of glycolysis (Krieg et.al, 
2004). Further research needs to be done to 
understand the correlation between the COX 
proteomics and its link to metabolic 
alteration. 
Another study has shown the 
correlation between altered COX function 
and the Warburg effect, a hallmark of 
metabolic reprogramming. In this study, two 
of the 10 nuclear encoded COX subunits, 
IVi1 and Vb were knocked down to disrupt 
the COX normal function (Srinivasan et.al, 
2016). These cytochrome c oxidase knock 
down (COXKD) cells showed a loss of 
COX activity, which was linked to the 
metabolic switch to glycolysis. The knock 
down of either subunit showed an increase 
in HK and phosphofructokinase (PFK) in 
cells. This led to an increase in glucose 
consumption and GLUT4 mRNA levels by 
greater than 2 folds compared to normal 
cells. However, the level of GLUT-1 was 
not affected, which is quite interesting as 
GLUT-1 is found in high levels in many 
cancer types. All these observations show a 
link between the disrupted COX and 
metabolic reprogramming in cancer cells. 
The COXKD cells were observed to have 
invasive phenotype, a decrease in 
transmembrane potential, and upregulation 
of genes that regulate cell growth, motility, 
invasiveness, and other hall marks of cancer 
cells. The induction of tumorigenesis may 
potentially be caused by defected COX, 
which may very well be used as a biomarker 
(Srinivasan et.al, 2016). 
ATP Synthase (Complex V) 
ATP Synthase (ATPs), also known 
as complex V, is a part of the OP metabolic 
pathway. It is involved in the catalysis of 
ATP synthesis by forming 
phosphoanhydride bond between ADP and 
Pi, as well as in the decomposition of ATP 
to ADP and Pi, and thus serves as the rate 
limiting step in OS (Whitford, 2005). ATPs 
is located on the inner membrane of 
mitochondria and has two domains, Fo and 
F1, both of which are known to have 
different biological and chemical properties. 
Fo is the hydrophobic domain embedded in 
the inner mitochondrial membrane where it 
functions as a proton translocator using the 
proton gradient created by the electron 
transport chain. F1 is the hydrophilic domain 
located in the mitochondrial matrix and 
consists of 5 different subunits. Fo and F1 
domains of ATPs work together by using the 
energy generated from the proton gradient to 
form or break the phosphoanhydride bonds 
for the synthesis or decomposition of ATP 
(Whitford, 2005). 
ATPs plays an important role in 
human carcinoma, and its malfunction is 
known to be involved in mediation and 
progression of different types of human 
pathologies (Cenizo et.al, 2010). Studies 
have shown the importance of ATPs and 
how the malfunctioning could contribute in 
carcinogenesis. In normal cells, a protein 
known as inhibitory factor 1 (IF1) is known 
to prevent ATPs from shifting to ATP 
hydrolysis under hypoxic conditions. The 
expression of IF1 varies among different 
tissues, as it is highly expressed in heart, 
moderately in liver, and almost negligible in 
breast, colon, and lung. In human 
carcinoma, studies have shown that IF1 is 
found in abundance even in the cells that 
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once had negligible levels. This resulted in 
the malfunctioning of ATPs and promoted 
the switch to high rates of aerobic 
glycolysis. As expected, the silencing of IF1 
was shown to have reverse effects as it 
decreased the rate of glycolysis (Arago et.al, 
2012). What causes the upregulation of IF1 
is still unknown. One may wonder what 
causes IF1 to not interfere with ATPs 
activity when it is highly expressed in 
normal tissues such as the heart. It is 
hypothesized that perhaps the IF1 protein 
goes through post-translational 
modifications which do not allow it to 
interfere with normal ATPs activity and 
perhaps that modification is subdued in 
carcinoma (Arago et.al, 2012). 
In another study, elevated expression of 
IF1 was shown to be involved in mediating 
the switch to Warburg phenotypes by 
regulating tumor metabolism through ATPs 
activity. Monoclonal antibodies were used 
against IF1 to show high expression of IF1 
in human carcinomas compared to normal 
cells and high levels were shown to increase 
the rate of aerobic glycolysis with a decrease 
in OP. The silencing of IF1 had the opposite 
effects as a decrease in the rate of aerobic 
glycolysis and an increase in the rate of OP 
was observed. These observations were 
correlated to the Warburg effect in this study 
(Cenizo et. al, 2010).  
5. P53 
P53, also known as TP53, is a well-
known tumor suppressor encoded by a 
tumor suppressor gene. A tumor suppressor 
gene is an anti-oncogene that regulates cell 
cycle by slowing down cell division, 
repairing DNA, and inducing apoptosis 
when necessary. One of the hallmarks of 
cancer cells is its ability to evade tumor 
suppression (Weinberg & Hanahan, 2011).  
P53 gene is located on chromosome 
number 7 and it is a phosphoprotein with 
393 amino acids that build its 4 domains 
(Bioinformatics). Each domain has a distinct 
function to activate transcription factors, 
recognize specific DNA sequences, 
tetramerize the protein, or recognize DNA 
damage.  
P53 also regulates mouse double minute 
2 (Mdm2), also known as E3 ubiquitin-
protein ligase, encoded by the Mdm2 gene, 
and uses it to regulate its own levels. P53 
proteins that are not phosphorylated binds to 
Mdm2, which then degrades it through 
ubiquitination (Bioinformatics). P53 helps 
maintain the cell’s genome stability by 
preventing mutations through regulating 
DNA damage repair proteins (Jones 
&Thompson, 2009). Low levels of P53 are 
present in normal cells which are activated 
and increased if the cell has been insulted 
with DNA damage, hypoxia, and oxidative 
stress, shunting the cell to go under 
apoptosis (Jones & Thompson, 2009). 
With the tumor suppressor functions, 
P53 also has an important role in terms of 
metabolism. It has the ability to reduce the 
glycolytic flux, thus oppose the Warburg 
effect (Hirschey, et.al, 2015). 
Approximately 50% of all tumors have 
mutations in p53 (Bioinformatics). 
Energy homeostasis pathways are 
regulated by stress-induced transcriptional 
programs, which in turn are regulated by 
p53 (Jones & Thompson, 2009). When a cell 
goes under hypoxia induced oxidative stress, 
the level of (cyclic adenosine 
monophosphate) cAMP:ATP increases 
which activates 5’ adenosine 
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monophosphate-activated protein  kinase 
(AMPK), which then not only activates p53 
but also inhibits lipid and protein synthesis, 
crucial for cell growth. The increase in p53 
then triggers a protein called TIGAR (TP53-
inducible glycolysis and apoptosis 
regulator), which inhibits the glycolytic 
pathway.  
Studies have also shown that the activity 
of P53 favors the formation of ATP from 
OP, which is common in normal cells (Jones 
& Thompson, 2009). It does this by 
regulating fructose-2-6-biphosphate (in the 
glycolytic pathway), TIGAR, and the 
assembly of COX by cytochrome c oxidase 
assembly protein (SCO2). It is interesting to 
note that a lack of SCO2 assists the cell to 
shift from OS to glycolysis to generate ATP 
(Jones & Thompson, 2009).  
Another study has shown an interesting 
relationship between PKM2 and p53. An 
increase in PKM2 resulted in a decrease in 
p53 protein level with a short half-life (Wu, 
et.al, 2016). However, when PKM2 was 
knocked down in the cell, the p53 level 
increased with a greater half-life. It was also 
observed that PKM2 is capable of directly 
binding to p53 and MDM2 complex and 
promote p53 ubiquitination (dimeric form of 
PKM2 has a greater significance) (Wu, et.al, 
2016).  
Defects or a loss in P53 results in 
abnormal cell proliferation, which is one of 
the hall marks of cancer. This provides a 
great growth opportunity for normal cells to 
transform in to cancer cells. When normal 
cells are insulted with multiple DNA 
damage, hypoxic oxidative stress, and other 
cell insults, the absence of p53 would mean 
the absence of repair mechanism and 
apoptosis induction, allowing the cell to 
behave abnormally (Jones & Thompson, 
2009). The silencing or complete loss of P53 
allows the switch in the metabolism from 
OP to glycolysis without blocking the cell 
cycle and inducing apoptosis.  
 
Table. 1: Compares the significance of GLUT-1, 
HK, PKM, SD, CS, COX, ATPs, and P53 in cancer 
verses normal cells. 
Conclusion 
All that is known about cancer and 
the advances in treatment seen today have 
been a direct result of a terrifying historical 
background. It was an era of trial and error 
in the scientific community where thousands 
of cancer patients had no choice but to go 
through treatments that were nothing more 
than an educated guess from doctors and 
scientists. The patients ended up having 
severe side effects, making the approach to 
death as horrific as it could be. The trials 
ranged from directly injecting toxins in 
patients with no knowledge of dosage and 
side effects, to performing radical 
mastectomy with no knowledge of what 
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cancer actually is and how it metastasizes. It 
is important to note, however, that all of this 
was done with an intention to save lives 
because the rate of patients coming in with 
cancer was increasing and scientists did not 
understand what cancer is, let alone know 
how to cure it. (Mukherjee & Burns, 2015). 
Research in mitochondria has 
enabled us to discover the differences in the 
structure and function of this organelle 
between normal and cancer cells. These 
differences have been used to develop novel 
site-specific targets for chemotherapy. 
Mitochondria-targeted drugs or 
mitochondria-anticancer agents (mitocans) 
have shown both efficacy and selectivity to 
kill cancer cells in pre-clinical and early 
clinical trials. However, these drugs as 
single agents are not yet sufficient to go 
beyond phase III clinical trials, which 
requires high selectivity, efficacy, and low 
toxicity (Napolitano & Weissig, 2015). This 
challenge has led scientist to come up with 
new strategies to enhance the selectivity of 
mitocans to achieve the desired results in 
vitro and vivo.  
Further research on mitochondria 
and targeting it for cancer therapies will 
undoubtedly lead to new drug discoveries 
and new methods that will enable us to 
create more efficient and selective 
treatments for a variety of cancers. Perhaps 
it may take another era to ultimately save all 
the lives suffering from cancer, but progress 
is what gives us hope and the battle against 
cancer will continue. 
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